Cervical Cancer
according to the data are recorded 2100 new cases of cervical cancer annually, with an annual mortality of 740 women, representing each day die in this country two people for this kind of disease, which is situated between the second and third most common malignancy in women in Spain between 15 and 44. According to scientists, according to epidemiological data in Spain, as elsewhere in Europe, are 16 and 18 genotypes of human papillomavirus (HPV) that are associated with 70% of all cases and compared to which the efficacy of Cervarix vaccine is nearly 100%, as demonstrated by this trial.
These results are extremely good even among girls who have participated in the study and have not fully respected the established protocol, so even having no contact with the papilloma, limited medical treatment to only two doses of vaccine, instead of three fixed, as explained above, among others, the head of Obstetrics and Gynecology Service of Hospital San Carlos in Madrid, Dr. Jose Antonio Vidart.
Another of the advantages of this vaccine, as those responsible for research, is that it provides a very high cross-protection of individual versus three other HPV genotypes other than those mentioned, in particular, as compared to types 31, 33 and 45 that are most cervical cancer cases occur after 16 and 18.